What You Should Know:
- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS (“Policlinico Gemelli”) to establish an in-house liquid biopsy testing service as a part of its diagnostics services within its hospital system.
- Leveraging Guardant Health’s cutting-edge proprietary digital sequencing platform, this initiative will include on-site analysis of Guardant360® CDx liquid biopsy tests directly within the Policlinico Gemelli facilities in Rome, Italy.
Guardant Health: Advancing Precision Oncology and Expanding Global Cancer Care
Transforming Cancer Diagnostics Through Innovative Technology
Founded in 2012, Guardant Health is a leader in precision oncology, dedicated to improving patient outcomes by offering advanced blood and tissue tests, real-world data, and AI analytics. Guardant’s tests play a pivotal role across the cancer care spectrum, from early-stage screening and recurrence monitoring to guiding treatment decisions for advanced cancers. Their mission is to extend the time patients can live free from cancer.
Global Expansion and Collaboration in Italy
Guardant Health’s partnership with Policlinico Gemelli, one of Italy’s largest hospitals, establishes one of the first liquid biopsy testing facilities housed within a hospital system in the country. This collaboration highlights Guardant’s commitment to expanding access to cutting-edge cancer diagnostics, enhancing patient care, and improving outcomes globally. Policlinico Gemelli serves thousands of cancer patients annually, offering advanced oncology services and research.
European Certification and Ongoing Impact on Cancer Care
In 2024, Guardant Health’s Guardant360® CDx blood test received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746). This certification allows for tumor mutation profiling across all solid tumors and supports companion diagnostic indications for targeted therapies, specifically for advanced non-small cell lung cancer and breast cancer. Guardant Health’s liquid biopsy tests are used by oncologists worldwide, as well as in clinical trials, to accelerate precision medicine drug development.
“Gemelli, one of the most important Italian and European oncology centers, can now offer its patients more state-of-the-art diagnostics for precision oncology through this innovative test. This partnership with Guardant Health represents a fundamental step for our hospital,” said Professor Giovanni Scambia, Scientific Director of Policlinico Gemelli.
